MExbrain

Executive Summary

MExbrain is a French clinical-stage biotech developing MEX-CD1, a superchelating polymer used in conjunction with a dialysis machine to extract free metals from the blood. The company is initially targeting Wilson's Disease (copper overload) and Acute Kidney Injury (AKI, associated with metal toxicity). MEX-CD1 offers a novel mechanism of action, potentially addressing unmet needs in these indications. The company is currently in Phase 1 clinical development, having been founded in 2021. Its technology differentiates from traditional chelators by providing efficient, extracorporeal metal removal, which may reduce systemic toxicity and improve patient outcomes. The company remains private with disclosed funding or valuation. The lead indication, Wilson's Disease, is a rare genetic disorder with existing therapies but significant room for improvement in managing acute crises. The AKI application opens a larger market opportunity, though competition and regulatory hurdles are notable. MExbrain's early stage and lack of public data imply high risk, but the technology's novelty could attract partnership interest from larger dialysis or rare disease players.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 data readout for MEX-CD1 in Wilson's Disease40% success
• Q4 2026Strategic partnership or licensing deal with a dialysis or rare disease company35% success
• Q3 2026Series A financing or non-dilutive grant to advance clinical development60% success